Overview

Detailed Summary

Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development.
The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly.
Wockhardt's rich pipeline includes multiple new chemical entities (NCEs), unique antibiotics that address superbug challenges, illustrating its leadership in novel antibiotic discovery, especially with successful Phase 3 trials for drugs like ZAYNICH.
Wockhardt plans to double its business in the next three years by expanding capacity and tapping into the growing demand for its diabetes and novel antibiotic portfolios, highlighting strategic growth plans.
It has garnered significant global recognition with Qualified Infectious Disease Programme status for five antibacterial drugs from the USFDA, underlining its global standing in addressing serious infectious diseases.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
Market Cap: 22,582 Cr
Volatility: High Risk
P/E Ratio: 182.5
Industry P/E: 28.5
PEG Ratio: 2.1
P/B Ratio: 4.9
52W High: 1,870.00
52W Low: 1,109.60

Sales CAGR

1Y: 7.65%
3Y: -2.30%
5Y: 1.15%
10Y: -4.25%

Profit CAGR

1Y: 87.92%
3Y: —
5Y: —
10Y: —

ROE

TTM: 1.54%
3Y: -8.92%
5Y: -3.14%
10Y: -3.89%

ROCE

TTM: 4.05%
3Y: -1.31%
5Y: -2.53%
10Y: -1.35%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
JBCHEPHARM	1973.60	31,750 Cr	42.03	8.34	0.76	18.88	25.16	16.00
EMCURE	1468.00	27,879 Cr	30.76	5.88	0.20	16.72	19.37	9.53
WOCKPHARMA	1397.90	22,582 Cr	182.49	4.94	0.00	1.54	4.05	-0.12
NATCOPHARM	882.55	15,807 Cr	10.15	1.83	0.68	17.79	21.15	14.81
GRANULES	563.50	13,688 Cr	25.17	3.44	0.27	12.88	13.37	7.86
CONCORDBIO	1166.45	12,203 Cr	38.75	6.68	0.75	17.73	23.48	15.38
COHANCE	304.95	11,712 Cr	38.80	3.09	0.00	10.47	11.28	4.65

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	753	701	700	739	809	721	743	738	782	888
Expenses	681	664	803	648	699	593	679	666	604	711
Operating Profit	72	37	-103	91	110	128	64	72	178	177
OPM %	9.56	5.28	-14.71	12.31	13.60	17.75	8.61	9.76	22.76	19.93
Other Income	24	8.00	54	30	9.00	8.00	15	-77	21	15
Interest	76	77	73	73	73	60	48	48	55	60
Depreciation	55	55	58	54	55	55	53	56	53	65
Profit Before Tax	-35	-87	-180	-6.00	-9.00	21	-22	-109	91	67
Tax %	-108.57	1.15	1.67	-166.67	-77.78	4.76	-104.55	0.92	9.89	8.96
Net Profit	-73	-86	-177	-16	-16	20	-45	-108	82	61
EPS in Rs	-4.76	-5.10	-10.99	-0.90	-1.39	0.91	-1.57	-5.53	4.81	3.61

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	4,015	3,937	3,566	2,844	2,708	3,230	2,651	2,798	3,012	3,011
Expenses	4,002	3,935	3,604	2,725	2,771	2,932	2,550	2,759	2,619	2,637
Operating Profit	13	1.83	-38	119	-63	298	101	39	393	374
OPM %	0.32	0.05	-1.08	4.19	-2.33	9.23	3.81	1.39	13.05	12.42
Other Income	114	-238	21	39	-10	-163	-172	69	62	-45
Interest	225	255	265	276	249	299	302	305	254	229
Depreciation	149	150	164	224	246	247	251	223	217	219
Profit Before Tax	-247	-641	-447	-342	-568	-411	-624	-420	-16	-119
Tax %	8.54	-4.01	30.18	59.67	47.71	32.12	0.48	-12.38	-256.25	-25.21
Net Profit	-226	-667	-312	-138	-297	-279	-621	-472	-57	-149
EPS in Rs	-13.10	-38.23	-12.86	-4.30	41.98	-18.09	-34.38	-29.08	-2.94	1.32
Dividend Payout %	-56.47	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	55	55	55	55	55	55	72	72	77	81
Reserves	3,720	3,281	2,797	2,619	2,616	3,321	3,777	3,282	3,282	4,272
Borrowings	2,471	3,853	2,610	2,453	2,514	2,674	2,198	2,184	2,356	2,021
Other Liabilities	1,875	1,832	2,700	2,716	2,993	1,724	2,196	2,145	1,934	1,761
Total Liabilities	8,121	9,022	8,162	7,844	8,179	7,774	8,243	7,683	7,649	8,135
Fixed Assets	2,809	2,773	2,888	3,058	3,502	3,343	3,462	3,042	2,881	2,736
CWIP	1,036	1,244	1,433	1,445	1,585	1,379	1,342	1,539	1,722	2,033
Investments	0.45	563	214	0.45	0.45	0.00	0.00	0.00	0.00	422
Other Assets	4,276	4,442	3,628	3,340	3,092	3,052	3,439	3,102	3,046	2,944
Total Assets	8,121	9,022	8,162	7,844	8,179	7,774	8,243	7,683	7,649	8,135

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	-42	-269	68	183	649	-287	413	153	219	-22
Cash from Investing Activity	-106	-687	630	95	-156	1,470	-201	-125	-137	-783
Cash from Financing Activity	193	1,254	-769	-776	-680	-1,171	-71	-315	334	409
Net Cash Flow	46	298	-71	-499	-186	12	141	-287	416	-396

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Nov 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	58.40%	55.14%	54.93%	51.60%	51.99%	51.99%	49.09%	49.09%	49.09%	49.09%	49.08%	49.08%
FIIs	2.59%	3.01%	4.16%	5.49%	5.92%	6.69%	6.61%	6.54%	6.81%	7.28%	7.09%	6.99%
DIIs	0.20%	0.23%	0.35%	4.85%	4.47%	5.11%	9.90%	9.84%	10.61%	11.03%	11.03%	10.57%
Public	38.81%	41.61%	40.56%	38.06%	37.61%	36.21%	34.39%	34.53%	33.50%	32.60%	32.79%	33.35%
Total Shareholders	1,78,915	1,72,989	1,61,813	1,46,138	1,40,391	1,38,142	1,43,876	1,42,710	1,41,799	1,46,918	1,37,946	1,42,274

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q3 FY24

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY23

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY22

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Regulatory Filing

6 days ago

Monitoring Agency Report for QIP Utilization

Monitoring Agency Report confirming no deviations in the utilization of QIP funds for Wockhardt Limited for the quarter ended December 31, 2025.

Financial Results

6 days ago

Wockhardt Reports Q3 Financial Results

Wockhardt Limited released its financial results for Q3FY26, highlighting a 22% revenue growth and a 72% increase in EBITDA compared to the previous year.

Board Meeting Outcome

6 days ago

Board Meeting Outcome: Un-Audited Financial Results Approved

The Board of Directors approved the Un-Audited Financial Results for the quarter and nine months ended December 31, 2025, during a meeting held on February 10, 2026.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Wockhardt Ltd

Wockhardt Ltd (WOCKPHARMA) is currently trading at 1,404.05 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Wockhardt Limited is a global pharmaceutical and biotechnology company with a strong focus on research-driven pharmaceuticals, particularly in antibiotics and biotech drug development. The company achieved a notable 67% growth in EBITDA in the past year, driven by operational excellence and significant debt reduction initiatives, improving its financial health markedly. Wockhardt's rich pipeline includes multiple new chemical entities (NCEs), unique antibiotics that address superbug challenges, illustrating its leadership in novel antibiotic discovery, especially with successful Phase 3 trials for drugs like ZAYNICH. Wockhardt plans to double its business in the next three years by expanding capacity and tapping into the growing demand for its diabetes and novel antibiotic portfolios, highlighting strategic growth plans. It has garnered significant global recognition with Qualified Infectious Disease Programme status for five antibacterial drugs from the USFDA, underlining its global standing in addressing serious infectious diseases.

Over the past 52 weeks, Wockhardt Ltd has traded between a low of ₹1,109.60 and a high of ₹1,870.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Wockhardt Ltd has a market capitalization of approximately 22,582.35. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Wockhardt Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 182.49 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 22,582.35 Cr, Wockhardt Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Wockhardt Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 182.49. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

In Q3 FY26, Wockhardt's consolidated revenue grew by 23.2% YoY to ₹888 crore, and its consolidated net profit surged by 205% YoY to ₹61 crore from ₹20 crore in the previous year.

In Q3 FY26, Wockhardt reported a 22% year-on-year revenue increase to ₹888 crore, a 72% surge in EBITDA to ₹173 crore, and a 3% rise in net profit to ₹27.5 crore.

The Biopharma Shakti initiative, with a 10,000 crore rupee outlay, directly benefits Wockhardt by fostering domestic production of biologics and biosimilars, strengthening the R&D ecosystem, and improving clinical trial infrastructure, all crucial for Wockhardt's novel drug development.

Zaynich is a novel antibiotic developed by Wockhardt to combat severe, multi-drug-resistant bacterial infections. It has received fast-track assessment status from regulators in both the US and Europe due to its potential to address urgent, unmet medical needs.

Wockhardt Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Documents

Actions

Announcements

Monitoring Agency Report for QIP Utilization

Wockhardt Reports Q3 Financial Results

Board Meeting Outcome: Un-Audited Financial Results Approved

AI Mode

Ask AI

Frequently Asked Questions about Wockhardt Ltd

What is Wockhardt Ltd share price today?

What does Wockhardt Ltd do?

What is the 52-week high and low of Wockhardt Ltd?

What is the market capitalization of Wockhardt Ltd?

Should I consider investing in Wockhardt Ltd stock?

Is Wockhardt Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Wockhardt Ltd belong to and why does it matter?

What is the PE ratio of Wockhardt Ltd?

What were Wockhardt's key financial highlights in Q3 FY26?

What were Wockhardt's key financial highlights in Q3 FY26?

How does the Biopharma Shakti initiative impact Wockhardt Ltd?

What is Wockhardt's new antibiotic, Zaynich?

Utility

Company

Technicals

Documents

Frequently Asked Questions about Wockhardt Ltd

What is Wockhardt Ltd share price today?

What does Wockhardt Ltd do?

What is the 52-week high and low of Wockhardt Ltd?

What is the market capitalization of Wockhardt Ltd?

Should I consider investing in Wockhardt Ltd stock?

Is Wockhardt Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Wockhardt Ltd belong to and why does it matter?

What is the PE ratio of Wockhardt Ltd?

What were Wockhardt's key financial highlights in Q3 FY26?

What were Wockhardt's key financial highlights in Q3 FY26?

How does the Biopharma Shakti initiative impact Wockhardt Ltd?

What is Wockhardt's new antibiotic, Zaynich?

Forecasts

Projection

Announcements

Monitoring Agency Report for QIP Utilization

Wockhardt Reports Q3 Financial Results

Board Meeting Outcome: Un-Audited Financial Results Approved

Peers

Price Chart Comparison

Oscillators

Neutral

Overall

Bullish

Moving Averages

Bullish

Overall

Bullish

Overview

Financial Ratios

Investment Checklist